{"entity":{"id":"nct06488378","kind":"trial","name":"Axatilimab and olaparib in BRCA/PALB2-associated metastatic breast cancer","aka":[],"tldr":"This early study combines a DNA-repair drug with a treatment targeting macrophages in advanced breast cancer. It is recruiting, with strict lung-history requirements.","summary":"Registry status recruiting, last updated 2026-09-02. Enrollment is 20 estimated. Metastatic or unresectable HER2-negative breast cancer with a deleterious or suspected deleterious germline/somatic BRCA1/2 mutation or germline PALB2 mutation, documented by a CLIA-certified laboratory. Axatilimab targets CSF1R and is combined with olaparib in phase 1b. The registry excludes a history of pneumonitis or ILD, or baseline evidence of either. Dana-Farber and Mayo are listed recruiting; cohort/site slots need confirmation. This human two-drug study is distinct from preclinical three-drug PARP/CSF1R/SREBP1 experiments and does not establish adjuvant efficacy.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT06488378","url":"https://clinicaltrials.gov/study/NCT06488378"}],"tags":[],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib","axatilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06488378","phase":"1","setting":"Metastatic or unresectable HER2-negative breast cancer with a deleterious or suspected deleterious germline/somatic BRCA1/2 mutation or germline PALB2 mutation, documented by a CLIA-certified laboratory","sponsor":"Dana-Farber Cancer Institute","started":"2024-08-13","startedType":"actual","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06488378/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"axatilimab","kind":"drug","name":"Axatilimab","route":"/drugs/axatilimab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}]}}